Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients

American Journal of Kidney Diseases

Volumn 57, Issue 5, 2011, Pages 724-732

  Lee, Bruce Y ^a,b   Stalter, Randy M ^a,b   Bacon, Kristina M ^a,b   Tai, Julie H Y ^a,b   Bailey, Rachel R ^a,b,c   Zimmer, Shanta M ^a   Wagner, Michael M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

computer model; computer simulation; cost effectiveness; end stage renal disease; hemodialysis; immunodeficiency; Influenza vaccine; seasonal influenza; vaccine adjuvant

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NON PRESCRIPTION DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG POTENCY; FEMALE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; LIFE EXPECTANCY; LONG TERM CARE; MALE; MEDICAL DECISION MAKING; MORTALITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; STOCHASTIC MODEL; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 79954468244     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.12.016     Document Type: Article

References (66)

1. M.J. Sarnak, and B.L. Jaber Pulmonary infectious mortality among patients with end-stage renal disease Chest 120 6 2001 1883 1887 (Pubitemid 34053449)
2. S.B. Naqvi, and A.J. Collins Infectious complications in chronic kidney disease Adv Chronic Kidney Dis 13 3 2006 199 204 (Pubitemid 43947730)
3. D.T. Gilbertson, M. Unruh, A.M. McBean, A.T. Kausz, J.J. Snyder, and A.J. Collins Influenza vaccine delivery and effectiveness in end-stage renal disease Kidney Int 63 2 2003 738 743 (Pubitemid 36126822)
4. N.P. Vogtlander, A. Brown, R.M. Valentijn, G.F. Rimmelzwaan, and A.D. Osterhaus Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients Vaccine 22 17-18 2004 2199 2201 (Pubitemid 38626058)
5. P. Rautenberg, I. Teifke, T. Schlegelberger, and U. Ullmann Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination Infection 16 6 1988 323 328 (Pubitemid 19004302)
6. C. Cavdar, M. Sayan, and A. Sifil The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients Scand J Urol Nephrol 37 1 2003 71 76 (Pubitemid 36246218)
7. W.E. Beyer, D.J. Versluis, P. Kramer, P.P. Diderich, W. Weimar, and N. Masurel Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components Vaccine 5 1 1987 43 48 (Pubitemid 17015108)
8. J.A. Antonen, P.M. Hannula, R. Pyhala, H.H. Saha, I.O. Ala-Houhala, and A.I. Pasternack Adequate seroresponse to influenza vaccination in dialysis patients Nephron 86 1 2000 56 61
9. K.M. Kunisaki, and E.N. Janoff Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses Lancet Infect Dis 9 8 2009 493 504
10. US Renal Data System USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2009 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
11. V. Baldo, T. Menegon, C. Bonello, A. Floreani, and R. Trivello Comparison of three different influenza vaccines in institutionalised elderly Vaccine 19 25-26 2001 3472 3475 (Pubitemid 32710298)
12. A. Banzhoff, P. Nacci, and A. Podda A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis Gerontology 49 3 2003 177 184 (Pubitemid 36438758)
13. S. De Donato, D. Granoff, and M. Minutello Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly Vaccine 17 23-24 1999 3094 3101 (Pubitemid 29366990)
14. R. Li, H. Fang, Y. Li, Y. Liu, M. Pellegrini, and A. Podda Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects Immun Ageing 5 2008 2
15. J. Puig Barbera, and D. Gonzalez Vidal MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations Expert Rev Vaccines 6 5 2007 659 665
16. S. Squarcione, S. Sgricia, L.R. Biasio, and E. Perinetti Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects Vaccine 21 11-12 2003 1268 1274 (Pubitemid 36139959)
17. M.L. Mbow, E. De Gregorio, N.M. Valiante, and R. Rappuoli New adjuvants for human vaccines Curr Opin Immunol 22 3 2010 411 416
18. A. Naso A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine ClinicalTrials.gov Identifier: NCT01031966 www.clinicaltrials.gov Accessed June 7, 2009
19. B.Y. Lee, A.K. Ercius, and K.J. Smith A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population Vaccine 27 16 2009 2251 2257
20. PDR Red Book 2009 Thompson Healthcare Inc Montvale, NJ
21. Centers for Medicare & Medicaid Services Physician Fee Schedule www.cms.hhs.gov 2009 Accessed June 7, 2009
22. US Bureau of Labor Statistics National Compensation Survey: Occupational Wages in the United States, June 2006 2007 US Department of Labor Washington, DC
23. M. Milenkovic, C.A. Russo, and A. Elixhauser Characteristics of all hospital stays and stays with a principal diagnosis of influenza www.hcup-us.ahrq.gov/reports 2005 Accessed June 9, 2010
24. K. Smith, and M. Roberts Cost-effectiveness of newer treatment strategies for influenza Am J Med 113 4 2002 300 307
25. J.F. Modlin, D.E. Snider, and R.D. Clover Preventioncontrol of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 48 RR-4 1999 1 28
26. A.G. Windquist, K. Fukuda, C.B. Bridges, and N.J. Cox Neuraminidase inhibitors for treatment of influenza A and B infections MMWR Recomm Rep 48 RR-14 1999 1 9
27. L.V. Gubareva, L. Kaiser, and F.G. Hayden Influenza virus neuraminidase inhibitors Lancet 355 9206 2000 827 835 (Pubitemid 30128828)
28. F.G. Hayden, A.D. Osterhaus, and J.J. Treanor Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections GG167 Influenza Study Group N Engl J Med 337 13 1997 874 880 (Pubitemid 27408569)
29. T.O. Jefferson, V. Demicheli, J.J. Deeks, and D. Rivetti Amantadine and rimantadine for preventing and treating influenza A in adults Cochrane Database Syst Rev 2 2000 CD001169
30. J.J. Treanor, F.G. Hayden, and P.S. Vrooman Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial US Oral Neuraminidase Study Group JAMA 283 8 2000 1016 1024 (Pubitemid 30112215)
31. T.O. Tengs, and A. Wallace One thousand health-related quality-of-life estimates Med Care 38 6 2000 583 637
32. D.L. Sackett, and G.W. Torrance The utility of different health states as perceived by the general public J Chronic Dis 31 11 1978 697 704
33. D. Rivetti, T. Jefferson, and R. Thomas Vaccines for preventing influenza in the elderly Cochrane Database Syst Rev 3 2006 CD004876
34. N.A. Molinari, I.R. Ortega-Sanchez, and M.L. Messonnier The annual impact of seasonal influenza in the US: measuring disease burden and costs Vaccine 25 27 2007 5086 5096 (Pubitemid 46879994)
35. I. Looijmans-Van den Akker, T.J. Verheij, E. Buskens, K.L. Nichol, G.E. Rutten, and E. Hak Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients Diabetes Care 29 8 2006 1771 1776 (Pubitemid 44156628)
36. J.M. Langley, L. Frenette, and L. Ferguson Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults J Infect Dis 201 11 2010 1644 1653
37. F. Roman, T. Vaman, B. Gerlach, A. Markendorf, P. Gillard, and J.M. Devaster Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial Vaccine 28 7 2010 1740 1745
38. T.W. Clark, M. Pareek, and K. Hoschler Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine N Engl J Med 361 25 2009 2424 2435
39. V. Demicheli, D. Rivetti, J.J. Deeks, and T.O. Jefferson Vaccines for preventing influenza in healthy adults Cochrane Database Syst Rev 3 2004 CD001269
40. J. Scharpe, W.E. Peetermans, and J. Vanwalleghem Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial Am J Kidney Dis 54 1 2009 77 85
41. D.S. Shepard Cost-effectiveness in Health and Medicine M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, 1996 Oxford University Press New York J Ment Health Policy Econ 2 2 1999 91 92
42. A.E. Fiore, D.K. Shay, and K. Broder Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 MMWR Recomm Rep 58 RR-8 2009 1 52
43. R.J. Diepersloot, K.P. Bouter, and J.B. Hoekstra Influenza infection and diabetes mellitus Case for annual vaccination Diabetes Care 13 8 1990 876 882 (Pubitemid 20331543)
44. L.B. Brydak, and M. Machala Humoral immune response to influenza vaccination in patients from high risk groups Drugs 60 1 2000 35 53 (Pubitemid 30601315)
45. A. Laupacis, D. Feeny, A.S. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 4 1992 473 481
46. B. Descamps-Latscha The immune system in end-stage renal disease Curr Opin Nephrol Hypertens 2 6 1993 883 891
47. B. Descamps-Latscha, A. Herbelin, and A.T. Nguyen Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis Relationships with activation markers of T cells, B cells, and monocytes J Immunol 154 2 1995 882 892
48. B.J. Pereira, L. Shapiro, A.J. King, M.E. Falagas, J.A. Strom, and C.A. Dinarello Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients Kidney Int 45 3 1994 890 896
49. + T cells to extracellular matrix ligands in patients with end-stage renal failure Isr Med Assoc J 2 4 2000 282 286 (Pubitemid 30662201)
50. U. Anandh, B. Bastani, and S. Ballal Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients Am J Nephrol 20 1 2000 53 56 (Pubitemid 30047871)
51. F. Fabrizi, S.V. Ganeshan, V. Dixit, and P. Martin Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease Aliment Pharmacol Ther 24 5 2006 789 796
52. R. Jha, S. Lakhtakia, M.A. Jaleel, G. Narayan, and K. Hemlatha Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders Ren Fail 23 5 2001 629 636 (Pubitemid 33055235)
53. N.P. Singh, S.K. Mandal, and A. Thakur Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failureresults of a prospective, randomized trial Ren Fail 25 2 2003 255 266 (Pubitemid 36529668)
54. K. Sudhagar, S. Chandrasekar, M.S. Rao, and R. Ravichandran Effect of granulocyte macrophage colony stimulating factor on hepatitis-B vaccination in haemodialysis patients J Assoc Physicians India 47 6 1999 602 604
55. D. Kapoor, S.R. Aggarwal, N.P. Singh, V. Thakur, and S.K. Sarin Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients J Viral Hepat 6 5 1999 405 409 (Pubitemid 29470171)
56. E. Tanzi, A. Amendola, and E. Pariani Lack of effect of a booster dose of influenza vaccine in hemodialysis patients J Med Virol 79 8 2007 1176 1179 (Pubitemid 47015418)
57. A. Carmona, F. Omenaca, and J.C. Tejedor Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months Vaccine 28 36 2010 5837 5844
58. C.S. Waddington, W.T. Walker, and C. Oeser Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study BMJ 340 2010 c2649
59. J. Diez-Domingo, M. Garces-Sanchez, and J.M. Baldo Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study Pediatr Infect Dis J 29 6 2010 e35 e46
60. T.F. Schwarz, T. Horacek, and M. Knuf Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults Vaccine 27 45 2009 6284 6290
61. I. Leroux-Roels, F. Roman, and S. Forgus Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study Vaccine 28 3 2010 849 857
62. D.W. Chu, S.J. Hwang, and F.S. Lim Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults Vaccine 27 52 2009 7428 7435
63. T. Jones GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection Curr Opin Mol Ther 11 3 2009 337 345
64. Dikow R, Eckerle I, Ksoll-Rudek D, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03A-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis., in press.
65. B.Y. Lee, and D.S. Burke Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles Vaccine 28 16 2010 2806 2809
66. J.J. Snyder, and A.J. Collins Association of preventive health care with atherosclerotic heart disease and mortality in CKD J Am Soc Nephrol 20 7 2009 1614 1622